DALLAS, Feb. 12, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biopharmaceutical company Rexahn Pharmaceuticals Inc. (AMEX:RNN). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/RNN
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Rexahn Pharmaceuticals Inc. (RNN) is a biopharmaceutical company engaged in the development and commercialization of drug therapies for various forms of cancers, central nervous system disorders as well as other pathologies and disease. The Company is a clinical stage drug maker. Three clinical drug candidates under development include Archexin™, Serdaxin™ and Zoraxel™.
Message Board Search for RNN: http://www.boardcentral.com/boards/RNN
In the report, the analyst notes:
"Archexin™ (RX-0201) is the Company's lead cancer drug candidate, and is currently in phase II clinical trials. Archexin has shown early indications as an effective drug to treat patients with pancreatic cancer, renal cell carcinoma and possibly other forms of cancer. The Food and Drug Administration (FDA) has granted Archexin orphan drug status for the treatment of five tumor types, including glioblastoma, pancreatic, stomach, ovarian and renal cell tumors. Archexin has shown signs of effectively reducing AKT in cancer cells of some solid tumors.
"Serdaxin™ is under development to treat patients with depression, anxiety and neurodegenerative disorders. Serdaxin is currently in phase II clinical trials for major depressive disorder. Unlike other SSRIs and SNRIs, which inhibit an "overactive" re-uptake valve in the brain, Serdaxin increases the body's natural production of neurotransmitters serotonin and dopamine."
To read the entire report visit: http://www.beaconequity.com/i/RNN
See what investors are saying about these stocks at penny stock forum
BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.